Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 84Breast Neoplasms 10Neoplasm Metastasis 7Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 3Castration-resistant Prostate Cancer 3Triple Negative Breast Neoplasms 2Castration Resistant Metastatic Prostate Cancer 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Primary Breast Cancer ER+ve 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Progressive Castration-resistant Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × enzalutamide × Clear all
NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡